

## Biophytis Joins Silver Innov', an Incubator Dedicated to the Silver Economy

**Paris, France, Cambridge (Massachusetts, USA), July 30<sup>th</sup>, 2025 – 7:00 AM** – Biophytis SA ("the Company"), a pioneering company in the development of transformative therapies for obesity, sarcopenia, and longevity, is relocating to Silver Innov', an incubator and business center specialized in innovation, healthcare, and aging.

This move represents a key milestone in Biophytis' strategic roadmap, reinforcing its presence within an ecosystem dedicated to the silver economy, healthy aging, and biopharmaceutical innovation.

As of this July, Biophytis has moved into the Silver Innov' premises in Ivry-sur-Seine, joining a dynamic community of companies focused on senior healthcare challenges. Silver Innov' offers a flexible and connected working environment designed to foster synergies between academic, hospital, and industrial stakeholders, notably through its partnerships with Sorbonne University, the Île-de-France Region, and several major hospitals in the Paris area.

*"Our relocation to Silver Innov' aligns perfectly with our DNA and ambition to lead innovation in the field of longevity. This environment enables us to strengthen our interactions with leading academic and clinical research stakeholders in aging, while evolving in a stimulating and future-oriented setting,"* said Stanislas Veillet, CEO of Biophytis.

This new location brings Biophytis closer to a key ecosystem dedicated to health and aging, while also consolidating its longstanding ties with Sorbonne laboratories in Jussieu, where the Company continues its research activities. This move is fully in line with Biophytis' scientific anchoring and multidisciplinary partnership strategy at the intersection of research, healthcare innovation, and public policy related to aging.

### About Silver Innov'

Silver Innov' is an incubator and business center located in Ivry-sur-Seine, dedicated to innovative companies working toward healthy aging. It offers modular office spaces, shared areas that promote collaboration, and personalized support. Backed by leading academic and hospital institutions, Silver Innov' is now a central player in the silver economy in the Île-de-France region.

More information [here](#)

### About BIOPHYTIS

Biophytis SA is a clinical-stage biotechnology company focused on developing drug candidates for age-related diseases. BIO101 (20-hydroxyecdysone), our lead drug candidate, is a small molecule in development for muscular diseases (sarcopenia, Phase 3 ready to start) and metabolic disorders (obesity, Phase 2 ready to start). The company is headquartered in Paris, France, with subsidiaries in Cambridge, Massachusetts, USA, and Brazil. The Company's

## Press release

ordinary shares are listed on Euronext Growth Paris (ALBPS - FR001400OLP5) and its ADS (American Depositary Shares) are listed on the OTC market (BPTSY - US 09076G401). For more information, visit [www.biophytis.com](http://www.biophytis.com).

### Disclaimer

This press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. In some cases, you can identify these forward-looking statements by the use of words such as "outlook," "believes," "expects," "potential," "continues," "may," "will," "should," "could," "seeks," "predicts," "intends," "trends," "plans," "estimates," "anticipates" or the negative version of these words or other comparable words. Such forward-looking statements are based on assumptions that Biophytis considers to be reasonable. However, there can be no assurance that the statements contained in such forward-looking statements will be verified, which are subject to various risks and uncertainties. The forward-looking statements contained in this press release are also subject to risks not yet known to Biophytis or not currently considered material by Biophytis. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. Please also refer to the "Risk and uncertainties the Company is to face" section from the Company's 2023 Financial Report available on BIOPHYTIS website ([www.biophytis.com](http://www.biophytis.com)) and as exposed in the "Risk Factors" section of form 20-F as well as other forms filed with the SEC (Securities and Exchange Commission, USA). We undertake no obligation to publicly update or review any forward-looking statement, whether because of new information or otherwise, except as required by law.

### Biophytis Contacts

#### Investor Relations

[Investors@biophytis.com](mailto:Investors@biophytis.com)

#### US Investors

Pascal Nigen – Alpha Bronze

[pnigen@alphabronzellc.com](mailto:pnigen@alphabronzellc.com)

#### Media contacts

Antoine Denry: [antoine.denry@taddeo.fr](mailto:antoine.denry@taddeo.fr) – +33 6 18 07 83 27

Inès de Mandiargues: [ines.demandiargues@taddeo.fr](mailto:ines.demandiargues@taddeo.fr) - +33 6 16 16 51 78